Novavax (NVAX) Stock Statistics & Valuation Metrics

Novavax has a market cap or net worth of $942.55M. The enterprise value is $618.06M.

Novavax has 160.84M shares outstanding. The number of shares has decreased by -2.65% in one year.

Novavax’s return on equity (ROE) is 0.30 and return on invested capital (ROIC) is -63.99%.

The current PE Ratio of Novavax is -6.53. Novavax’s PEG ratio is 0.08.

In the last 12 months, Novavax had revenue of $682.16M and earned -$187.50M in profits. Earnings per share was -$1.21.

In the last 12 months, operating cash flow was -$87.26M and capital expenditures -$13.38M, giving a free cash flow of -$100.64M billion.

Novavax pays an annual dividend of , resulting in a dividend yield of

Novavax upcoming earnings date is May 7, 2025, After Close.

Novavax as a current ratio of 0.98, with Debt / Equity ratio of -0.37

In the past 12 months, Novavax has paid $10.88M in taxes.

Novavax EV to EBITDA ratio is -8.55, with an EV/FCF ratio of -9.21.

Novavax has $923.12M in cash and marketable securities with $230.42M in debt, giving a net cash position of -$692.70M billion.

Gross margin is 70.28%, with operating margin of -36.49%, and net profit margin of -27.49%.

The average price target for Novavax is $14.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy